Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb's 2017 Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for "Golden Tickets," which underwrite the cost of one lab bench for one year in LabCentral's Kendall Square facility.

"We are delighted to award Golden Tickets to Neutrolis and Remora Therapeutics, two emerging, innovative companies with significant scientific potential," said Carl Decicco, Ph.D., Head of Discovery at Bristol-Myers Squibb. "The winners align with our commitment to enabling scientific innovation in our research areas of focus. We look forward to seeing these promising companies advance their research programs at LabCentral. Our sponsorship of LabCentral has facilitated important collaborations between Bristol-Myers Squibb researchers and the Cambridge community, as we prepare for our research site opening in Cambridge next year."

Neutrolis is a preclinical drug discovery company focused on researching new potential treatment options for inflammatory diseases where uncontrolled neutrophilic inflammation may be implicated, such as lupus and sepsis. Neutrophils are the predominant white blood cells present during acute inflammation. When patients are unable to regulate this inflammatory process, it can lead to worsening of disease. Using its proprietary genetic technology platform, Neutrolis is developing therapeutics with the goal of neutralizing excessive neutrophilic inflammation, as well as companion diagnostics to identify patients who are most likely to benefit from such therapeutics.

Remora Therapeutics is a preclinical-stage biotechnology company focused on developing novel platelet-based cell therapies. Platelets are best known for their role in blood clotting, but they are also involved in the pathogenesis of many major human diseases, including cancer and conditions of autoimmunity. Remora’s proprietary technology is designed to engineer platelets to fight disease, and improve the quality of life for patients living with debilitating illness.

"Bristol-Myers Squibb’s first two Golden Ticket winners, PanTher and Suono Bio, have each met important research milestones and have been terrific contributors to the LabCentral community," commented LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D. "We are pleased to welcome Neutrolis and Remora Therapeutics - impressive startups - and we expect that they will likewise thrive here."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About LabCentral

LabCentral is a first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub. Designed as a launchpad for high-potential life-sciences and biotech startups, it offers everything startups need to begin laboratory operations on day one and move their science forward faster and more cost-efficiently. This includes: fully permitted laboratory and office space, first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series - as well as the other critical services and support. A private, nonprofit institution, LabCentral's first site opened in 2013, thanks to a capital grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation. To accommodate demand for its growing startups, LabCentral, with support from Pfizer, Inc., plans to open LabCentral 610 in December 2017. In 2018, LabCentral will have capacity to serve a total of ~450 scientists and entrepreneurs in about 70 companies across its two-building campus.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]